257 related articles for article (PubMed ID: 16932505)
1. Technology Insight: imaging amyloid plaques in the living brain with positron emission tomography and MRI.
Huddleston DE; Small SA
Nat Clin Pract Neurol; 2005 Dec; 1(2):96-105. PubMed ID: 16932505
[TBL] [Abstract][Full Text] [Related]
2. [Amyloid-plaque imaging of the brain using PET].
Ossenkoppele R; Tolboom N; Pijnenburg YA; Lammertsma AA; Scheltens P; van Berckel BN
Ned Tijdschr Geneeskd; 2011; 155():A2981. PubMed ID: 21586182
[TBL] [Abstract][Full Text] [Related]
3. A novel 18F-labeled pyridyl benzofuran derivative for imaging of β-amyloid plaques in Alzheimer's brains.
Cheng Y; Ono M; Kimura H; Kagawa S; Nishii R; Saji H
Bioorg Med Chem Lett; 2010 Oct; 20(20):6141-4. PubMed ID: 20817524
[TBL] [Abstract][Full Text] [Related]
4. [The contribution of nuclear medicine procedures in the diagnosis of dementia of Alzheimer's type. Imaging beta amyloid plaques].
Tsolaki M; Trontzos C; Kazis A
Hell J Nucl Med; 2005; 8(3):187-90. PubMed ID: 16390030
[TBL] [Abstract][Full Text] [Related]
5. Beta amyloid imaging with positron emission tomography (PET) for evaluation of suspected Alzheimer's disease or other causes of cognitive decline.
Technol Eval Cent Assess Program Exec Summ; 2013 Feb; 27(5):1-4. PubMed ID: 23589929
[No Abstract] [Full Text] [Related]
6. Compounds for imaging amyloid-β deposits in an Alzheimer's brain: a patent review.
Tu P; Fu H; Cui M
Expert Opin Ther Pat; 2015 Apr; 25(4):413-23. PubMed ID: 25746836
[TBL] [Abstract][Full Text] [Related]
7. Multitracer PET imaging of amyloid plaques and neurofibrillary tangles in Alzheimer's disease.
Shin J; Lee SY; Kim SH; Kim YB; Cho SJ
Neuroimage; 2008 Nov; 43(2):236-44. PubMed ID: 18694837
[TBL] [Abstract][Full Text] [Related]
8. 18F-labeled flavones for in vivo imaging of beta-amyloid plaques in Alzheimer's brains.
Ono M; Watanabe R; Kawashima H; Kawai T; Watanabe H; Haratake M; Saji H; Nakayama M
Bioorg Med Chem; 2009 Mar; 17(5):2069-76. PubMed ID: 19201614
[TBL] [Abstract][Full Text] [Related]
9. Validation of an (18)F-labeled biphenylalkyne as a positron emission tomography imaging agent for beta-amyloid plaques.
Wey SP; Weng CC; Lin KJ; Yao CH; Yen TC; Kung HF; Skovronsky D; Kung MP
Nucl Med Biol; 2009 May; 36(4):411-7. PubMed ID: 19423009
[TBL] [Abstract][Full Text] [Related]
10. Biopsy support for the validity of Pittsburgh compound B positron emission tomography with a twist.
Klunk WE
Arch Neurol; 2008 Oct; 65(10):1281-3. PubMed ID: 18852340
[No Abstract] [Full Text] [Related]
11. The synthesis and characterization of [(124)I]IMPY, a thioflavin-S derivative, in transgenic mouse models of Alzheimer's disease.
Chang KW; Chen CC; Lee SY; Shen LH; Wang HE
Appl Radiat Isot; 2009; 67(7-8):1397-400. PubMed ID: 19307132
[TBL] [Abstract][Full Text] [Related]
12. Quantitative analysis of amyloid plaques in a mouse model of Alzheimer's disease by phase-contrast X-ray computed tomography.
Noda-Saita K; Yoneyama A; Shitaka Y; Hirai Y; Terai K; Wu J; Takeda T; Hyodo K; Osakabe N; Yamaguchi T; Okada M
Neuroscience; 2006; 138(4):1205-13. PubMed ID: 16460878
[TBL] [Abstract][Full Text] [Related]
13. 18F-barbiturates are PET tracers with diagnostic potential in Alzheimer's disease.
Calamai E; Dall'Angelo S; Koss D; Domarkas J; McCarthy TJ; Mingarelli M; Riedel G; Schweiger LF; Welch A; Platt B; Zanda M
Chem Commun (Camb); 2013 Jan; 49(8):792-4. PubMed ID: 23235438
[TBL] [Abstract][Full Text] [Related]
14. Florbetapir (18F) for brain amyloid positron emission tomography: highlights on the European marketing approval.
Cortes-Blanco A; Prieto-Yerro C; Martinez-Lazaro R; Zamora J; Jiménez-Huete A; Haberkamp M; Pohly J; Enzmann H; Zinserling J; Strassmann V; Broich K
Alzheimers Dement; 2014 Oct; 10(5 Suppl):S395-9. PubMed ID: 24418060
[TBL] [Abstract][Full Text] [Related]
15. 18F stilbenes and styrylpyridines for PET imaging of A beta plaques in Alzheimer's disease: a miniperspective.
Kung HF; Choi SR; Qu W; Zhang W; Skovronsky D
J Med Chem; 2010 Feb; 53(3):933-41. PubMed ID: 19845387
[No Abstract] [Full Text] [Related]
16. Picture imperfect: Going beyond imaging amyloid in Alzheimer's disease.
Kincaid E
Nat Med; 2016 Oct; 22(10):1067-1068. PubMed ID: 27711060
[No Abstract] [Full Text] [Related]
17. Amyloid imaging using high-field magnetic resonance.
Amatsubo T; Yanagisawa D; Morikawa S; Taguchi H; Tooyama I
Magn Reson Med Sci; 2010; 9(3):95-9. PubMed ID: 20885081
[TBL] [Abstract][Full Text] [Related]
18. Amyloid imaging using fluorine-19 magnetic resonance imaging ((19)F-MRI).
Tooyama I; Yanagisawa D; Taguchi H; Kato T; Hirao K; Shirai N; Sogabe T; Ibrahim NF; Inubushi T; Morikawa S
Ageing Res Rev; 2016 Sep; 30():85-94. PubMed ID: 26772439
[TBL] [Abstract][Full Text] [Related]
19. A copper radiopharmaceutical for diagnostic imaging of Alzheimer's disease: a bis(thiosemicarbazonato)copper(II) complex that binds to amyloid-beta plaques.
Lim S; Paterson BM; Fodero-Tavoletti MT; O'Keefe GJ; Cappai R; Barnham KJ; Villemagne VL; Donnelly PS
Chem Commun (Camb); 2010 Aug; 46(30):5437-9. PubMed ID: 20556304
[TBL] [Abstract][Full Text] [Related]
20. The merits of FDDNP-PET imaging in Alzheimer's disease.
Shin J; Kepe V; Barrio JR; Small GW
J Alzheimers Dis; 2011; 26 Suppl 3():135-45. PubMed ID: 21971458
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
